Lawrence Livermore National Laboratory, 7000 East Avenue, Livermore, CA 94550

A -- LAWRENCE LIVERMORE NATIONAL LABORATORY SEEKS PARTNERSHIPS WITH INDUSTRY TO COMMERCIALIZE TECHNOLOGIES FOR DETECTING AND QUANTIFYING CHROMOSOME ABERRATIONS SOL CBD99-014 POC Not Applicable WEB: Click here to download the U.S. Patents related to, http://www.llnl.gov/IPandC/Technology/techno-license.html/. Lawrence Livermore National Laboratory (LLNL), operated by the University of California under contract with the U.S. Department of Energy (DOE), is seeking industrial partners to commercialize technologies for detecting and quantifying nucleic acid sequences. LLNL has developed nucleic acid hybridization technologies for detecting and quantifying nucleic acids, including whole chromosomes, in solution. Methods are based on probes and probe combinations that allow both capture of target nucleic acids on solid supports and quantification of the captured targets by a variety of means. The technologies are particularly useful for identifying and quantifying nucleic acid sequence aberrations such as chromosomal rearrangements and deletions that are characteristic of many blood cell cancers and solid tumors and for evaluating effects of ionizing radiation and other environmental agents on frequency of nucleic acid aberrations. Because probe immobilization on a solid support may occur prior to hybridization,the technologies may be used in a DNA chip format for screening purposes. The present methods increase by several fold, the sensitivity, precision and speed of detecting nucleic acid sequence aberrations over related detection methods including fluorescence in situ hybridization (FISH), which make them effective for early detection of disease and disease recurrence. Because the methods do not rely on nucleic acid amplification to achieve sensitivity, they avoid the problem of sample contamination by amplicons from prior tests. LLNL's nucleic acid hybridization technologies are described in US Patents 5616465, 5731153, and 5783387, which may be read on the Featured Technologies page at website http://www.llnl.gov/IPandC/Technology/techno-license.html/. Note: This is not a procurement. Companies interested in commercializing LLNL's nucleic acid hybridization technology should provide a written statement of interest that must include a commercialization plan and a description of corporate capability and experience relevant to commercializing these technologies. Statements of interest should be sent to: Lawrence Livermore National Laboratory Industrial Partnerships and Commercialization Office PO Box 808, L-795 Livermore, CA 94551 Attention: CBD99-014 Posted 04/26/99 (W-SN324398). (0116)

Loren Data Corp. http://www.ld.com (SYN# 0002 19990428\A-0002.SOL)